Portal de Periódicos da CAPES

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood

2016; Elsevier BV; Volume: 51; Linguagem: Inglês

10.1016/j.clinbiochem.2016.09.015

1873-2933

Kazunori Murata, Samuel I. McCash, Brittany L. Carroll, Alexander M. Lesokhin, Hani Hassoun, Nikoletta Lendvai, Neha Korde, Sham Mailankody, Heather Landau, Guenther Koehne, David J. Chung, Sergio Giralt, Lakshmi V. Ramanathan, Ola Landgren,

Glycosylation and Glycoproteins Research

To characterize the effect of three humanized IgG κ monoclonal antibodies (daratumumab, isatuximab, and elotuzumab) on the interpretation of results generated by protein electrophoresis, immunofixation, free light chain, and heavy/light chain assays performed on human serum.Healthy volunteer serum and serum from multiple myeloma patients were supplemented with clinically relevant concentrations of each of the three monoclonal antibodies. These specimens then underwent analysis via serum protein electrophoresis, immunofixation, serum free light chain quantification, heavy/light chain quantification, total IgG, and total protein. In addition, serum specimens from patients who had undergone treatment with elotuzumab for multiple myeloma underwent similar analysis.Addition of the study drugs to serum from both the healthy donor as well as multiple myeloma patients resulted in a visible and quantifiable M-protein on SPEP and a visible IgGκ band by IFE. Increases were also noted in total IgG, IgGκ, and IgGκ/IgGλ-ratios. Analysis of serum from multiple myeloma patients receiving study drug showed similar findings with an additional IgGκ band and quantifiable M-protein with similar migration patterns in specimens drawn after administration.The treatment of multiple myeloma patients with monoclonal antibodies results in a visible and quantifiable M-protein that has the potential to falsely indicate poor response to therapy.